why choose us

First received: October 04, 2022

Clinical Trial: SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Metastatic Lung Non-Small Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 2 Trial of SX-682 and Pembrolizumab in Patients With Treatment Naive Stage IV or Recurrent Non-Small Cell Lung Cancer

Brief Summary: This phase II trial tests whether CXCR1/2 inhibitor SX-682 (SX-682) with pembrolizumab works to treat patients with stage IIIC or IV non-small cell lung cancer that has spread to other parts of the body (metastatic) or that has come back (recurrent).SX-682 is a drug that binds to receptors on some types of immune and cancer cells, inhibiting signaling pathways, reducing inflammation, and allowing other types of immune cells to kill and eliminate cancer cells.Pembrolizumab is a monoclonal antibody that binds…

Read more